Oragenics Inc. (NYSE American: OGEN) and Sigyn Therapeutics Inc. (OTCQB: SIGY) announced the signing of a letter of intent under which Oragenics expects to obtain an exclusive license to develop and commercialize Sigyn’s CardioDialysis™ blood purification technology for traumatic brain injury and chronic neurodegenerative diseases. This move complements Oragenics’ Phase IIa intranasal neurosteroid candidate ONP-002 in a proposed dual-modality approach targeting inflammation on both sides of the blood-brain barrier.
The importance of this announcement lies in its potential to address significant unmet medical needs in neurological care. Traumatic brain injury (TBI) and chronic neurodegenerative diseases such as Parkinson’s and Alzheimer’s remain challenging conditions with limited treatment options. By combining Oragenics’ intranasal delivery technology with CardioDialysis, the company aims to target inflammation systemically and within the brain, potentially offering a more comprehensive therapeutic approach.
Oragenics is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. The company is advancing its lead candidate, ONP-002, as a potential first-in-class treatment for concussion and mild traumatic brain injury. Oragenics is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. The company’s intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders.
The addition of CardioDialysis technology could expand Oragenics’ pipeline beyond intranasal delivery. CardioDialysis is a blood purification technology designed to remove inflammatory mediators from circulation. By reducing systemic inflammation, it may complement the effects of ONP-002, which targets inflammation within the brain. This dual-modality approach could be particularly relevant for conditions where inflammation plays a key role, such as chronic traumatic encephalopathy and other neurodegenerative disorders.
For the industry, this collaboration highlights the growing interest in combining different therapeutic modalities to tackle complex neurological diseases. The potential to address both sides of the blood-brain barrier could set a new precedent for treatment strategies. For patients and caregivers, the development of more effective therapies offers hope for improved outcomes and quality of life.
Investors should note that Oragenics is focused on innovative therapies for neurological care. The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN. The full press release can be viewed at https://ibn.fm/VD4RO.
